Translate 
Abstract
Background: The increasing utilization of interleukin‐17 (IL‐17) monoclonal antibody (MA) for psoriasis treatment, coupled with the high prevalence of hepatitis B virus (HBV), underscores the need for comprehensive safety data. This retrospective study aims to evaluate the safety of IL‐17 MA treatment in psoriasis patients with concurrent HBV infection.Research Design and Methods: The study screened 531 psoriasis patients treated with IL‐17 MA, ultimately enrolling 59 patients with abnormal HBV serological data. Outcomes assessed include HBV virological reactivation and changes in HBsAb serum quantification post‐IL‐17 MA therapy.Results: Laboratory data revealed HBV virological reactivation in two psoriasis patients classified as inactive HBV carriers (IBCs). Patients who had previously received HBV vaccination exhibited a significant decrease in HBsAb serum quantification following IL‐17 MA therapy.Conclusion: IL‐17 MA therapy presents a potential risk of HBV reactivation in psoriasis patients with HBV infection. Furthermore, IL‐17 MA appears to weaken HBV resistance in vaccinated patients.
Published Version
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
